Evaluation of histological and ultrastructural aspects of endometrium during treatment with gestrinone in women with amenorrhea or spotting.
Nineteen patients with a laparoscopic diagnosis of endometriosis were treated with gestrinone at a dosage of 2.5 mg twice a week for 6 months. In 7 who reported spotting in the first 3 months, the dose was increased to 2.5 mg three times a week during the second trimester. An endometrial sample was obtained from each patient at the time of laparoscopy (basal) and at 3 and 6 months of treatment. Endometrial structure and ultrastructure were studied. Areas of hemorrhage and of loss of surface epithelium and a lesser degree of involution of the surface epithelium were observed in the 3-month samples of 7 patients with spotting, compared with 12 with amenorrhea. It is hypothesized that incomplete endometrial involution could be due to differences in gestrinone pharmacokinetics in individual patients, in the quality and/or quantity of endometrial cytosolic receptors for sex steroids, or in endocrine compensation to administration of the drug.
Fedele
L
L
First Department of Obstetrics and Gynecology, University of Milan, Italy.
Marchini
M
M
Baglioni
A
A
Dell'Antonio
G
G
Motta
T
T
D000328:Adult; D000568:Amenorrhea / Q000209:etiology / Q000473:pathology*; D004715:Endometriosis / Q000188:drug therapy*; D004717:Endometrium / Q000648:ultrastructure*; D005260:Female; D005867:Gestrinone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009651:Norpregnatrienes / Q000627:therapeutic use*; D014592:Uterine Hemorrhage / Q000139:chemically induced / Q000473:pathology*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D009651:Norpregnatrienes; D005867:Gestrinone